Press Releases

 
Press Releases
  Date Title and Summary View
Oct 28, 2003
PITTSBURGH--(BUSINESS WIRE)--Oct. 28, 2003--Mylan Laboratories Inc. (NYSE: MYL) today announced it has signed an agreement for the sale of the U.S. and Canadian rights for Sertaconazole Nitrate 2% Cream (Sertaconazole) to the Ortho Neutrogena Division of Ortho-McNeil Pharmaceutical Inc. (Ortho Neutrogena) for $2 million and a future milestone ...
Oct 15, 2003
PITTSBURGH--(BUSINESS WIRE)--Oct. 15, 2003--Mylan Laboratories Inc. (NYSE: MYL) announced today that it will release its second quarter fiscal 2004 financial results after the market closes on Wednesday, October 29, 2003. Mylan management will host a conference call and live Webcast on Thursday, October 30, at 10:00 AM ET to discuss...
Oct 10, 2003
PITTSBURGH--(BUSINESS WIRE)--Oct. 10, 2003--Earlier this week, Mylan Laboratories Inc. (NYSE:MYL) reported it had been dismissed with prejudice from the consolidated, multi-district "Pharmaceutical Industry Average Wholesale Price Litigation" in the U.S. District Court for the District of Massachusetts. The dismissal was granted after presenta...
Oct 6, 2003
PITTSBURGH, Oct 6, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) today announced that all claims pending against it in the consolidated, multi-district "Pharmaceutical Industry Average Wholesale Price Litigation" in the U.S. District Court for the District of Massachusetts have been dismissed with prejudice. The AWP litigation ...
Sep 16, 2003
PITTSBURGH--(BUSINESS WIRE)--Sept. 16, 2003--Mylan Laboratories Inc. (NYSE:MYL) announced today that the Board of Directors has approved a three-for-two stock split of the Company's common shares. The split will be effected by issuing one additional share of common stock for every two shares of common stock held. The additional shares will be ...
Sep 16, 2003
PITTSBURGH, Sep 16, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has granted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Nefazodone Hydrochloride Tablets in 100 mg, 150 mg, 200 mg and 250 mg strengths. Nefazodone Hydrochloride i...
Sep 15, 2003
PITTSBURGH, Sep 15, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of $0.0333 per share will be paid on October 15, 2003, to shareholders of record on September 30, 2003. Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pha...
Sep 11, 2003
PITTSBURGH, Sep 11, 2003 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Midodrine Hydrochloride Tablets in 2.5 mg, 5 mg and 10 mg strengths. Midodrine Hydrochloride is the generic version of Shire Pharmac...
Aug 21, 2003
PITTSBURGH & CORONA, Calif.--(BUSINESS WIRE)--Aug. 21, 2003-- Supplemental Clinical Data Supporting Safety and Efficacy Provided to FDA Mylan Laboratories Inc. (NYSE:MYL) and Watson Pharmaceuticals, Inc. (NYSE:WPI) announced today that the U.S. Food and Drug Administration (FDA) has ac
Aug 8, 2003
PITTSBURGH--(BUSINESS WIRE)--Aug. 8, 2003--Contrary to the implications in Schwarz Pharma's August 7, 2003 press release, and after consultation with KUDCo's attorneys, Mylan Laboratories Inc. (NYSE: MYL) today confirms that KUDCo is not seeking to temporarily halt Mylan's sales of generic omeprazole capsules. Mylan initiated litiga...
Page: FirstPrevious ...
106
... NextLast
= add release to Briefcase